Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ATAI

AtaiBeckley Inc

7.27

Aug 18 • 10:19 AM ET +0.03 (0.36%)

Healthcare Biotechnology USA Mid NASD

Peers: ACAD AXSM INCY RYTM KRYS KYMR BMRN CRNX MDGL NBIX

| Held by: IWM VTI IWO IBB XPH VXF FYC VTWO PSIL SCHA

Scroll to Statements

Index	RUT
Market Cap	2.69B
Enterprise Value	2.47B
Income	-668.19M
Sales	4.47M
Book/sh	0.48
Cash/sh	0.61
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	117
IPO	Jun 18, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	602.83
P/B	15.21
P/C	11.93
P/FCF	-
EV/EBITDA	-
EV/Sales	552.76
Quick Ratio	8.58
Current Ratio	8.58
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.19
EPS next Y	-0.45
EPS next Q	-0.11
EPS this Y	85.11%
EPS next Y	-4.48%
EPS next 5Y	46.22%
EPS past 3/5Y	-43.86% 36.94%
Sales past 3/5Y	159.87% -
EPS Y/Y TTM	-172.00%
Sales Y/Y TTM	-
EPS Q/Q	36.07%
Sales Q/Q	137.00%
Earnings	May 12 BMO
EPS/Sales Surpr.	25.09% 339.43%

Insider Own	18.46%
Insider Trans	-0.21%
Inst Own	35.46%
Inst Trans	27.31%
ROA	-
ROE	-
ROIC	-375.52%
Gross Margin	-
Oper. Margin	-3274.31%
Profit Margin	-14938.36%
SMA20	0.82%
SMA50	24.05%
SMA200	61.81%
Trades

Shs Outstand	369.21M
Shs Float	302.39M
Short Float	6.57%
Short Ratio	1.70
Short Interest	19.86M
52W High	7.28 -0.19%
52W Low	3.27 122.54%
Volatility	0.42% 0.59%
ATR (14)	0.13
RSI (14)	72.19
Beta	1.55
Rel Volume	1.00
Avg Volume	11.71M
Volume	1,980,987

Perf Week	0.78%
Perf Month	1.06%
Perf Quarter	75.08%
Perf Half Y	91.21%
Perf YTD	77.65%
Perf Year	79.40%
Perf 3Y	359.87%
Perf 5Y	-53.72%
Perf 10Y	-
Recom	2.87
Target Price	7.93
Prev Close	7.24
Price	7.27
Change %	0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	Deutsche Bank	Buy	$12
Jan-20-26	Initiated	Guggenheim	Buy	$11
Oct-13-25	Initiated	Needham	Buy	$12
Jul-29-25	Initiated	Oppenheimer	Outperform	$14
Nov-18-24	Reiterated	H.C. Wainwright	Buy	$15 → $10
Apr-03-24	Upgrade	Maxim Group	Hold → Buy	$6
Nov-01-22	Initiated	Loop Capital	Buy	$18
Nov-30-21	Initiated	Maxim Group	Buy	$25
Nov-11-21	Initiated	ROTH Capital	Buy	$32
Oct-18-21	Initiated	H.C. Wainwright	Buy	$40
Sep-01-21	Initiated	Jefferies	Buy	$27
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform	$19
Jul-13-21	Initiated	Credit Suisse	Outperform	$25
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Citigroup	Buy	$26
Jul-13-21	Initiated	Cantor Fitzgerald	Buy	$45
Jul-13-21	Initiated	Canaccord Genuity	Buy	$28
Jul-13-21	Initiated	Berenberg	Buy	$35
Jul-08-21	Initiated	Aegis Capital	Buy	$26

Show Previous Ratings

Aug-17-26 09:16PM	Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-04-26 12:53PM	Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-02-26 06:26PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jul-22-26 01:25PM	Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva (IPO-Edge.com)
Jul-21-26 02:50PM	Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? (PR Newswire)
08:30AM	Loading…
08:30AM	Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates (PR Newswire)
Jul-17-26 01:06PM	Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal (Investor's Business Daily)
08:50AM	Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time (PR Newswire)
08:37AM	AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics (Proactive)
05:01AM	Eli Lilly's $3.8bn psychedelics bet is built on British science (Proactive)
Jul-16-26 06:17PM	Are ATAI, FHB, PATK Obtaining Fair Deals for their Shareholders? (PR Newswire) +33.40%
02:59PM	AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout (GuruFocus.com)
09:54AM	Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover (Investor's Business Daily)
09:23AM	Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy (Yahoo Finance)
08:51AM	UnitedHealth rallies premarket while chip stocks retreat; TSMCs record earnings (Investing.com)
08:41AM	Loading…
08:41AM	AtaiBeckley to be acquired by Eli Lilly in deal valued at up to $3.8 billion (Proactive)
08:01AM	Nasdaq dragged by chip sell-off, Abbott, UnitedHealth lead risers (Proactive)
08:01AM	Dow Jones called higher but Nasdaq lower, Lilley to acquire AtaiBeckley (Proactive)
07:44AM	Why Psychedelic stocks are surging today (Investing.com)
07:23AM	Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion (The Wall Street Journal)
07:13AM	?? Under the Radar: AtaiBeckley Stock Soars on Eli Lilly Deal (The Wall Street Journal)
06:45AM	Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions (PR Newswire)
06:33AM	GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS) (InvestorsHub)
06:30AM	AtaiBeckley shares soar on reports of potential Eli Lilly takeover talks (ATAI) (InvestorsHub)
05:36AM	This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks (Barrons.com)
Jul-14-26 03:00PM	The Race to Commercialize the Worlds Most Powerful Psychedelic (WSJ) +14.08%
Jul-13-26 02:59PM	Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says (Proactive)
Jul-07-26 12:47PM	AtaiBeckley set to unlock value from positive depression therapy trial results, says Jefferies (Proactive)
Jul-06-26 08:40AM	AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4 (Proactive)
06:00AM	AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder (GlobeNewswire)
09:03AM	Loading…
Jun-25-26 09:03AM	AtaiBeckley to join Russell 2000 and Russell 3000 indexes following annual reconstitution (Proactive) +9.83%
06:00AM	AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets (GlobeNewswire)
Jun-04-26 01:38PM	AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat Buy rating (Proactive)
May-28-26 09:57AM	AtaiBeckley launches mental health patient impact grant program (Proactive)
09:00AM	AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations (GlobeNewswire)
May-27-26 06:00AM	AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 (GlobeNewswire)
May-13-26 01:06PM	AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says (Proactive)
May-12-26 09:22AM	AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances (Proactive)
08:00AM	AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update (GlobeNewswire)
Apr-27-26 08:22AM	AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials (Proactive) -6.26%
04:05AM	AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research (GlobeNewswire)
Apr-24-26 03:59PM	FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit. (Barrons.com)
11:58AM	Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. (Barrons.com)
Apr-22-26 08:49AM	Can I have some, please?: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar (Moneywise)
Apr-20-26 12:41PM	Trump Signs Psychedelic Drugs Order. 4 Stocks That Are Surging. (Barrons.com) +21.59%
11:48AM	Trump Pushes for Speedy Psychedelic Approvals, Sending Stocks Surging (The Wall Street Journal)
09:56AM	Psychedelics stocks rise after Trump order expands research, access pathways (Proactive)
08:26AM	Psychedelic stocks rally with Trump's support (MarketWatch)
08:18AM	Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring. (Barrons.com)
05:53AM	Psychedelic stocks soar after Trump signs executive order to fast-track treatments (Investing.com)
Apr-14-26 11:18AM	Johnson & Johnsons Spravato sales growth signals upside for psychedelics peers (Proactive)
Apr-08-26 08:40AM	AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003 (Proactive)
06:00AM	AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs (GlobeNewswire)
Mar-29-26 10:25AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-27-26 11:25AM	AtaiBeckley awarded Buy rating in initial coverage from Deutsche Bank analysts (Proactive) -5.37%
Mar-24-26 08:36AM	AtaiBeckley added to major US indices, increasing reach among passive investors (Proactive)
06:00AM	AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst (GlobeNewswire)
Mar-17-26 09:09AM	AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003 (Proactive)
06:00AM	BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation (GlobeNewswire)
Mar-10-26 10:45AM	AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day (Proactive) +6.43%
06:00AM	BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day (GlobeNewswire)
Mar-09-26 10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire) +14.75%
Mar-08-26 12:57PM	AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 (Insider Monkey)
11:17AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
08:41AM	AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial (Proactive)
07:00AM	AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update (GlobeNewswire)
Mar-05-26 10:38AM	Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints (Benzinga)
Mar-04-26 11:40AM	AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting (Insider Monkey)
05:39AM	AtaiBeckley Inc (ATAI)'s Drug Candidate EMP-01 Shows Positive Results in Key Study (Insider Monkey)
Mar-03-26 08:07AM	AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing (Proactive)
07:00AM	AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression (GlobeNewswire)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
06:58AM	Cathie Wood "Buys the Dip" in Baidu Stock -- Should You? (GuruFocus.com)
Feb-26-26 03:49PM	Dow Jones back level but Nasdaq in the red thanks to Nvidia (Proactive) -14.06%
09:49AM	AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data (Benzinga)
09:47AM	AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial (Proactive)
07:00AM	AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder (GlobeNewswire)
Feb-20-26 07:00AM	AtaiBeckley To Host Virtual Investor Day on March 6, 2026 (GlobeNewswire)
Feb-19-26 03:30PM	Dow Jones leads Wall Street lower, US-Iran fears drive oil higher (Proactive)
08:21AM	AtaiBeckley names Michael Faerm as finance chief (Proactive)
07:00AM	AtaiBeckley Appoints Michael Faerm as Chief Financial Officer (GlobeNewswire)
Feb-17-26 07:00AM	AtaiBeckley To Participate in Upcoming Investor Conferences (GlobeNewswire) +6.44%
Feb-15-26 04:08AM	Wall Street Bullish on AtaiBeckley (ATAI), Here's Why (Insider Monkey)
Feb-13-26 11:44AM	Here's What Analysts Are Saying About AtaiBeckley Inc. (ATAI) (Insider Monkey)
07:13AM	AtaiBeckley Inc. (ATAI) Gains Momentum With Promising BPL-003 Data and Strong Analyst Support (Insider Monkey)
Jan-30-26 02:58PM	Guggenheim Initiates Buy Rating for AtaiBeckley (ATAI) With $11 PT, Cites Leadership in Psychiatry (Insider Monkey)
Jan-29-26 01:48PM	H.C. Wainwright Remains Bullish on AtaiBeckley Inc. (ATAI) (Insider Monkey)
Jan-19-26 11:28AM	High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (MarketBeat)
Jan-18-26 12:30PM	Atai Beckley N.V. (ATAI) Achieves Significant Milestone on Pipeline Development and Corporate Foundation (Insider Monkey)
Jan-16-26 07:00AM	AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation (GlobeNewswire)
Jan-14-26 02:13PM	Atai Beckley N.V. (ATAI) is a Buy on Mental Therapeutics Opportunities (Insider Monkey)
Jan-13-26 04:01AM	New Strong Sell Stocks for Jan. 13 (Zacks)
Jan-09-26 07:17AM	Atai Beckley CEO says entering 2026 with meaningful momentum (TipRanks) -5.54%
Jan-08-26 07:00AM	AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-26 04:51PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-30-25 06:55PM	AtaiBeckley Completes Redomiciliation to the United States (GlobeNewswire)
Dec-27-25 07:43AM	JonesTrading Highlights Differentiated Pipeline at Atai Beckley N.V. (ATAI) (Insider Monkey)
Dec-25-25 08:30AM	The 1 Riskiest Investment That Paid Off in 2025 (Barchart)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

Co-Founder & Chairman of the BoardMr. Christian Angermayer

Ph.D.Dr. Srinivas G. Rao M.D.

Chief Operating OfficerDr. Gerd G. Kochendoerfer Ph.D.

Chief Legal & Business OfficerMr. Ryan Barrett J.D.

Chief Financial OfficerMr. Michael Eric Faerm

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HERSHBERG ROBERT	Director	Jul 07 '26	Option Exercise	1.35	100,000	135,000	100,000	Jul 09 05:30 PM
HERSHBERG ROBERT	Director	Jul 07 '26	Sale	4.96	100,000	496,000	100,000	Jul 09 05:30 PM
ROBERT HERSHBERG	Director	Jul 07 '26	Proposed Sale	4.96	100,000	496,000		Jul 07 04:37 PM
GERD KOCHENDOERFER	Officer	Jun 26 '26	Proposed Sale	4.58	50,000	229,000		Jun 26 04:24 PM
KEVIN CRAIG	Officer	Jun 25 '26	Proposed Sale	4.17	85,158	355,109		Jun 25 04:27 PM
Craig Kevin James	Chief Medical Officer	Apr 20 '26	Option Exercise	1.62	42,579	69,070	51,016	Apr 22 05:32 PM
Craig Kevin James	Chief Medical Officer	Apr 20 '26	Sale	5.00	42,579	212,895	8,437	Apr 22 05:32 PM
KEVIN JAMES CRAIG	Officer	Apr 20 '26	Proposed Sale	4.03	42,579	171,593		Apr 20 04:34 PM
Angermayer Christian	Director	Apr 08 '26	Option Exercise	1.60	559,232	897,297	559,232	Apr 10 06:00 PM
KEVIN JAMES CRAIG	Officer	Mar 20 '26	Proposed Sale	3.57	100,000	357,000		Mar 20 04:41 PM
Feilding-Mellen Cosmo	Director	Feb 26 '26	Proposed Sale	4.00	750,000	3,000,000		Feb 26 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATAI

AtaiBeckley Inc

Upgrade your Finviz experience